Abstract
Limited studies have investigated the correlation between body composition and prostate cancer outcomes. We analyzed the effect of muscle mass and quality on castration-resistant prostate cancer (CRPC) outcomes. Skeletal muscle index (SMI) and skeletal muscle attenuation (SMA) were measured for 411 patients at the L3 vertebral level using computed tomography at CRPC diagnosis and were dived to low and high groups at the value of median. Analysis of the skeletal phenotypes and age (<70 and >70 years) was performed to evaluate the effect of SMI and SMA. The median survival rates for patients with low and high SMI were 19 and 24 months (p = 0.015), and those with low and high SMAs were 15 and 26 months (p < 0.001), respectively. In the subgroup analysis by age, SMA was a significant prognosticator in both groups, while SMI was a significant prognosticator only in patients aged >70 years. Patients with low SMA + low SMI had the worst prognosis. Muscle characteristics seems to be a prognosticator in survival of CRPC patients and may be considered in treatment planning.
Highlights
The incidence and prevalence of prostate cancer has increased because of various reasons [1].owing to the development of multimodal treatment and advancements in techniques, survival rates have increased [2]
Patients were stratified into two age groups, according to the median age of 70 years at castration-resistant prostate cancer (CRPC) diagnosis, and into four groups based on their skeletal muscle phenotype
In our our large large cohort cohort of of patients patients with with CRPC, CRPC, representative representative of of those those with with chronic chronic cancer cancer who who underwent underwent multimodal treatment, we found that that muscle muscle characteristics characteristics
Summary
The incidence and prevalence of prostate cancer has increased because of various reasons [1]. Owing to the development of multimodal treatment and advancements in techniques, survival rates have increased [2]. Some drugs are prescribed at a fixed dose for patients receiving chemotherapy, the dose is often determined based on the body surface area (BSA). Due to cachexia, sarcopenia, and obesity, varying toxicities and effectiveness are observed among patients with similar BSA ranges. Various researchers have concluded that the BSA should not be the main factor for dose determination. Many studies were conducted to analyze the association between individual body composition (including muscle and fat mass) and survival rates using various measurement techniques
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
